Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is yes. The Wegovy SmPC and patient information leaflet both advise removing the pen from the refrigerator and allowing it to reach room temperature for 30 minutes before you inject. Injecting a cold solution is not dangerous, but it does increase the chance of stinging and discomfort at the site. That practical detail is confirmed in Mounjaro and Wegovy's product information on the eMC, and the principle underpins NHS guidance on injectable weight-loss medicines more broadly. Semaglutide (Wegovy) is a prescription-only medicine requiring clinical assessment before a prescriber decides whether it is suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy patient information leaflet, published on the electronic Medicines Compendium (eMC), is the authoritative source here. It states that the pen should be taken from the fridge and left at room temperature for at least 30 minutes before injecting. That instruction exists for one straightforward reason: a solution at 2–8°C is cooler than the subcutaneous tissue it enters, and that temperature difference is what causes the sharp sting some people notice when they inject without waiting.
It is worth knowing what the guidance does not say. It does not say the pen is unsafe to inject cold, the medicine remains pharmacologically unchanged. The recommendation is purely about comfort and tolerability, which matters because stinging at the injection site can make people hesitant about their next dose. Consistency of dosing is central to how semaglutide works over weeks and months, so anything that removes a barrier to injection day is worth taking seriously.
Some people find that setting a 30-minute reminder at the same time each week builds the habit naturally, and our page on how long to leave Wegovy out before injecting walks through the timing in more detail, including what to do if your routine gets disrupted. A consistent routine also reduces the chance of forgetting the warm-up entirely.
The warm-up window is not open-ended. Your patient information leaflet specifies the maximum time Wegovy can remain unrefrigerated before it must be discarded. The precise figure is medicine-specific and can vary between formulations, which is why this page does not quote a single number: check your own leaflet, or ask the prescriber or pharmacist who looks after your treatment.
What the guidance does make clear is that once the pen has been out of the fridge beyond that permitted window, it should not be returned to the refrigerator and used at a later date. If you have let yours sit out too long, discard it in a sharps container and contact your prescriber about a replacement before your next scheduled dose.
One common misreading of the guidance is the idea that a longer warm-up is better. Thirty minutes is sufficient; leaving the pen out for several hours or overnight is not recommended and may compromise the medicine.
Temperature is one factor in injection comfort; site preparation is another. NHS guidance on semaglutide notes that the three licensed sites are the abdomen, the thigh, and the upper arm. Rotating between sites each week helps avoid localised skin thickening (lipohypertrophy), which can affect how the medicine is absorbed.
Technique details (such as whether to pinch the skin, the angle of insertion, and how long to hold the pen in place) are covered in the step-by-step guide to how to inject Wegovy. If you are considering the upper arm, you may also want to read the specific guidance on injecting Wegovy in the arm, since self-injection there requires a slightly different approach.
Wiping the site with an alcohol swab beforehand is standard practice; medical-grade alcohol swabs are the appropriate choice rather than household wipes.
The warm-up question does not sit in isolation. When you inject during the week, what you eat beforehand, and how you time the dose relative to any other oral medicines all interact with how well you tolerate the treatment. Our page on when to inject Wegovy covers the timing question in detail, and there is a separate guide on whether to eat before your injection that is worth reading alongside this one.
On pricing and what a private Wegovy prescription includes in the UK, the cost of Wegovy page sets out the honest picture, including what headline prices sometimes leave out.
Wegovy is a prescription-only medicine. A clinician needs to assess your full health picture before prescribing, factors including your current BMI, any comorbidities, other medicines you take, and your medical history all feed into that decision. If you are not yet on treatment and want to understand whether you might be suitable, our prescribers are the right place to start. Speak to our prescribers through a free consultation reviewed by a GPhC-registered Independent Prescriber, with no algorithm involved.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.